$HRTX

Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026

Heron Therapeutics announced it will report its first quarter 2026 financial results on Monday, May 11, 2026, through a conference call and live webcast. The event, scheduled for 8:30 a.m. ET, will also cover recent business highlights. Interested parties can access dial-in details via a registration link or the Investor Relations section of the company's website.

Original reporting
Published Apr 27, 2026, 9:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 27, 2026, 10:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026 — source image
Decision brief

The 30-second read

$HRTXNeutralMed
01

Why it matters

Earnings results will provide insights into the company's financial health and growth prospects, influencing stock performance.

02

Market read

The upcoming earnings report is a significant event for HRTX investors and could influence sector sentiment.

03

What to watch

Market-wide macroeconomic conditions and sector-specific news could overshadow earnings impact.

Timing: High, as the event is scheduled for May 11, 2026.

Background

Heron Therapeutics specializes in developing and commercializing therapies for pain management and other indications.

Company-level read

Ticker impact

$HRTXNeutralMedium confidence
Context

Heron Therapeutics upcoming earnings report scheduled for May 11, 2026, is the primary focus.

Expected impact

Potential short-term increase or decrease of 5-10% around the earnings date, contingent on results.

Evidence & confidence

Earnings reports often cause volatility; however, without prior earnings data or consensus estimates, the impact remains uncertain.

Market effects

Potential influence on the biotech and life sciences sectors depending on Heron Therapeutics' results.

Limited, primarily affecting US markets where the company is based.

Minimal, unless results significantly deviate from expectations, prompting broader biotech sector movements.

Counterpoint

Disappointing earnings could lead to a significant decline, suggesting caution in bullish positions.

Key entities

  • Heron Therapeutics

    A biotech firm focused on pain management therapies.

Related articles

$HRTXMedAI 8/10

Heron Therapeutics Q2 Earnings Call Highlights

Heron Therapeutics (NASDAQ:HRTX) reported Q2 sales of about $4.2M for APONVIE, up 26% QoQ and 74% YoY, and $21.8M for CINVANTI, down about 10% YoY. SUSTOL contributed $0.5M as wind-down continued. Heron posted a Q2 net loss of $5.5M, gross margin 69.3%, and ended with $42.7M cash equivalents. It amended its Hercules credit facility with a $13.5M principal reduction and potential $4M more, and withdrew 2026 guidance.

$HRTXMed

HERON THERAPEUTICS, INC. /DE/ (HRTX): Results of Operations and Financial Condition

HERON THERAPEUTICS, INC. /DE/ (HRTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 hrtx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Heron Therapeutics Announces Second Quarter 2026 Financial Results - Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF ® net revenue grew 35% and APONVIE ® net revenue grew 74% year-over-yea

$NVDAMed

Nvidia teams up with Wall Street asset managers on $500 billion AI infrastructure push

CNBC reports Nvidia is working with Apollo, Blackstone, BlackRock’s Global Infrastructure Partners, Brookfield, Goldman Sachs and KKR on a planned $500 billion financing push for AI infrastructure, citing an unnamed source. An announcement could come as soon as Monday, according to the report. The effort would help customers finance Nvidia GPUs and data centers, including power capacity needs.

$ARTWMed

Art's-Way Manufacturing Co.: Art's Way Announces Significant Increase in Backlog Following Award of Major Modular Building Projects

Art's-Way Manufacturing Co. (Nasdaq:ARTW) said its Modular Buildings segment backlog rose to over $19.0 million after winning major modular building projects. The company cited a prior $1.3 million backlog in its May 31, 2026 10-Q. It expects fulfillment by end of fiscal 2027, subject to schedules and milestones, with margins generally consistent with historical performance.